Which Aussies are presenting at ACR?

2 minute read

Rheumatologists from all over the world are heading to Atlanta for the ACR's annual meeting. Here are some of the Australians we’ve spotted in the program so far

Rheumatologists and researchers from all over the world will be heading to Atlanta, Georgia for the annual meeting of the American College of Rheumatology next week. Rheumatology Republic will be bringing you updates on the ground.

Here are some of the Australians that we’ve spotted in the program so far:

Clinical rheumatologist and head of the Monash Health Rheumatology Unit in Melbourne @EricFMorand

Professor Morand will lead a session looking into whether it’s time for a treat to target approach in SLE, as well as presenting his research into the effect of glucocorticoid-induced leucine zipper on the Type I interferon program in SLE.

Associate Professor Arnold’s session will focus on rheumatology in the outback, covering alternative practice models that are used in Australia to deliver care to the most remote regions of the country.

  • Dr David Liew
    Rheumatologist at Austin Hospital in Victoria @drdavidliew

Dr Liew will present his team’s research looking at inappropriate anti dsDNA antibody ordering in a large tertiary teaching hospital before and after the Evolve recommendations were promoted to limit testing of ANA-negative patients to cases where there was a high suspicion of SLE.

Associate Professor Grainger is presenting her team’s research into a smartphone app that was developed to enable people with rheumatoid arthritis to record their disease activity.

  • Professor Paul Bird
    Rheumatologist based in Kogarah in NSW and the director of Optimus Clinical Research @BirdCRP

Professor Bird’s presentation will focus on his team’s research evaluating the effectiveness and treatment patterns of tofacitinib in a large real-world cohort of Australian adult patients with RA.

Professor Thomas will present her team’s latest phase 1 clinical trial into the use of a novel nanoparticulate liposome formulation called DEN-181 to treat adult patients with ACPA+ RA.

End of content

No more pages to load

Log In Register ×